Managing Myeloproliferative Neoplasms: Practice Your Skills in These Virtual Patient Simulations Authors: Claire N. Harrison, DM, FRCP, FRCPath; Haifa Kathrin Al-Ali, MD

https://www.medscape.org/viewarticle/managing-myeloproliferative-neoplasms-practice-your-skills-2026a1000f5o?page=1&src=mkmcmr_driv_psims_mscpedu_260915-OUS-HONC-managing-myeloproliferative-neoplasms-practice-your-skills-2026a1000f5o-cta&uac=148436CN

Launching Bispecific Antibodies for Multiple Myeloma in Community Practice CME New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 am - 9:00 am CT Hybrid

https://na.eventscloud.com/website/98253/ Elevate your clinical practice in the rapidly evolving multiple myeloma (MM) landscape by joining our interactive, 90-minute symposium. Utilizing an innovative "newsroom format," this dynamic broadcast is tailored for hematologists, oncologists, and advanced practice providers ready to seamlessly integrate bispecific antibodies into individualized care plans. Gain critical, actionable insights into optimal patient selection and sequencing for novel monotherapies and combinations while overcoming adoption barriers in community settings. Master practical toxicity management protocols and discover how to establish the practice infrastructure needed to safely transition these therapies to outpatient care. Led by renowned expert faculty, this session provides the ultimate clinical playbook to expand therapeutic access and transform patient outcomes. Register now to stay ahead of the curve with tomorrow's emerging breakthroughs.

Nanobody cocktail shows promise as broad-spectrum antivenom A recombinant antivenom made of five nanobodies protected mice against lethal doses of venom from four medically important snake species in India. Written byAndrea Corona

Nanobody cocktail shows promise as broad-spectrum antivenom A recombinant antivenom made of five nanobodies protected mice against lethal doses of venom from four medically important snake species in India. Written byAndrea Corona https://www.drugdiscoverynews.com/nanobody-cocktail-shows-promise-as-broad-spectrum-antivenom-17530 Snakebite envenoming kills between 80,000 and 140,000 people worldwide each year, and India alone accounts for roughly 58,000 of those deaths, disproportionately affecting rural agricultural communities. Current treatment relies on antivenoms made by immunizing horses with venom, a decades-old approach that suffers from batch-to-batch variability, limited coverage of geographically distinct venoms, and risk of severe allergic reactions. In India, commercial antivenoms are formulated against the so-called "big four" snakes and often provide little protection against other clinically important species.

Challenging the Confines of Risk of Recurrence in High-Risk HR+/HER2- Early Breast Cancer Authors: Joyce A. O’Shaughnessy, MD; Priya Rastogi, MD; Seth Wander, MD, PhD

https://www.medscape.org/viewarticle/challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3?page=1&src=mkmcmr_driv_stan_mscpedu_260915-OUS-HONC-challenging-confines-risk-recurrence-high-risk-hr-her2-early-2026a1000bq3-cta&uac=148436CN

An America First Approach to Medical Innovation The FDA’s new Expedited IND Pilot will cut unnecessary delays in early-stage clinical research without compromising patient safety

https://www.fda.gov/news-events/fda-voices/america-first-approach-medical-innovation?utm_medium=email&utm_source=govdelivery An America First Approach to Medical Innovation America has long been the world’s premier destination for medical innovation. Our universities make groundbreaking discoveries. Our biotechnology companies turn them into medicines. Our capital markets finance risks few other countries can match. And the U.S. Food and Drug Administration ensures patient safety and efficacy. This leadership can’t be taken for granted. Today, a first-in-human clinical trial can take years to initiate in the United States versus just months in China and Australia. When clinical development happens faster overseas, America risks losing investment, intellectual property, scientific talent and, most important, early access to promising new therapies. That is why the FDA is launching the Expedited Investigational New Drug (IND) Pilot today. This is a key priority of the Trump Administration to retain American leadership in biomedical advancements.

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC Frederik Joelving September 15, 2026

https://www.medscape.com/viewarticle/first-line-t-dxd-boosts-pfs-her2-mutant-nsclc-2026a1000y2a?src= First-line trastuzumab deruxtecan (T-DXd; ENHERTU) improves progression-free survival compared with standard chemoimmunotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to new phase 3 data.

IMpower030: Atezolizumab Misses Primary Endpoint in NSCLC Megan Brooks September 15, 2026

https://www.medscape.com/viewarticle/impower030-atezolizumab-misses-primary-endpoint-nsclc-2026a1000y59?src= Adding perioperative atezolizumab to platinum-based chemotherapy nearly doubled median event-free survival (EFS) in patients with stage IIB-IIIB resectable non-small cell lung cancer (NSCLC) without EGFR or ALK alterations, but the improvement did not reach statistical significance in the final analysis of the phase 3 IMpower030 trial.